You are here

Recent Pfizer Press Releases

3/23/17 5:30pm EDT
FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

  • Only FDA-approved treatment for metastatic Merkel cell carcinoma, a rare and aggressive skin cancer  
  • First indication for BAVENCIO, a human anti-PD-L1 antibody 

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC). This indication is approved under accelerated approval based on tumor response and duration of response.

more...
3/23/17 4:20pm EDT
FDA Grants Approval for BAVENCIO® (avelumab)

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announce that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection 20 mg/mL, for intravenous use. 

The full prescribing information for BAVENCIO will be available at www.BAVENCIO.com.

more...
3/22/17 10:30am EDT
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 2, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2017 Performance Report, to be issued that morning.

more...
3/17/17 11:15am EDT
Bristol-Myers Squibb and Pfizer Present Large Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Patients with Non-Valvular Atrial Fibrillation

In this U.S. Medicare database analysis, Eliquis® (apixaban) was associated with significantly lower risk of stroke or systemic embolism and lower rate of major bleeding compared to warfarin

3/15/17 8:00pm EST
Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis

 

 

Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its oral Janus kinase (JAK) inhibitor, XELJANZ

more...
3/9/17 2:00am EST
Servier and Pfizer Announce FDA Clearance of IND Application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia

Servier, together with Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), announced today that the U.S. Food and Drug Administration (FDA) has granted Servier with an Investigational New Drug (IND) clearance to proceed in the U.S. with the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leukemia.

more...
3/8/17 8:00am EST
The Union for International Cancer Control and Pfizer Announce Next Phase of Global Grants Initiative Supporting Metastatic Breast Cancer Patients

Pfizer Commits Funding to Continue SPARC MBC Challenge Grants Partnership with UICC Bringing Total Funding to More Than $1.3 Million (USD)

In conjunction with International Women’s Day, The Union for International Cancer Control (UICC) and Pfizer Inc. today announced the next phase of their pioneering grants initiative to address the unique challenges facing metastatic breast cancer (mBC) patients around the globe. The Seeding Progress and Resources for the Cancer Community (SPARC): Metastatic Breast Cancer Challenge was designed to support the implementation of projects that address the specific needs of women with metastatic breast cancer globally - many of which extend beyond treatment.

more...
3/6/17 8:30am EST
Bristol-Myers Squibb and Pfizer to Present New Analyses of Eliquis™ (apixaban) Clinical and Real-World Data at the American College of Cardiology 2017 Scientific Session

  • Post-hoc Analyses from the ARISTOTLE Trial Featured in Late-Breaker and Poster Sessions 
  • Real-World Data Analyses Include Database Reviews of U.S. Medicare Patient Population 

3/6/17 8:00am EST
Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or Metformin 

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review three New Drug Applications (NDAs) for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes: one for monotherapy, one for the fixed-dose combination of ertugliflozin and JANUVIA® (sitagliptin), and one for the fixed-dose combination of ertugliflozin and metformin.

more...
2/28/17 6:53pm EST
Pfizer Prices €4,000,000,000 Debt Offering

Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of four tranches of notes:

€1,250,000,000 aggregate principal amount of floating rate notes due 2019

€1,000,000,000 aggregate principal amount of 0.000% notes due 2020

€1,000,000,000 aggregate principal amount of 0.250% notes due 2022

€750,000,000 aggregate principal amount of 1.000% notes due 2027

more...
2/28/17 10:00am EST
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by John Young, Group President, Pfizer Essential Health, at the Cowen and Company 37th Annual Healthcare Conference on Tuesday, March 7, 2017 at 11:20 a.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Cowen and Company 37th Annual Healthcare Conference” link in the For Investors section located on the lower right-hand corner of that page.

more...
2/28/17 7:00am EST
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review

Second Biologics License Application accepted by the FDA for avelumab

Prognosis for urothelial carcinoma is currently poor, particularly when the disease has metastasized

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, and Pfizer Inc. today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review EMD Serono's Biologics License Application (BLA) for avelumab* as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) with disease progression on or after platinum-based therapy. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 27, 2017, for avelumab in this indication.

more...
2/24/17 1:09pm EST
Pfizer Prices $1,065,000,000 Debt Offering

Pfizer Inc. (NYSE: PFE) today announced the pricing of $1,065,000,000 aggregate principal amount of 4.20% notes due 2047. This offering is expected to besold to professional institutional investors in Taiwan, with application to be made to list the notes on the Taipei Exchange.

Pfizer intends to use the net offering proceeds for general corporate purposes, including to repay a portion of its outstanding commercial paper.

The closing of the offering is expected to occur on March 17, 2017, subject to satisfaction of customary closing conditions.

more...
2/23/17 4:15pm EST
Ronald E. Blaylock Elected to Pfizer’s Board of Directors

Pfizer Inc. today announced the election of Ronald E. Blaylock to its Board of Directors, effective immediately. Mr. Blaylock was also appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.

more...
2/21/17 8:00am EST
Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration

Application Requests Approval for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults

Pfizer Inc. (NYSE:PFE) today announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

more...
2/17/17 12:00pm EST
New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a

Pfizer in partnership with Celltrion Healthcare presents new data for INFLECTRA in Crohn’s disease

Data announced jointly today by Pfizer Inc.

more...
2/16/17 8:00am EST
Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)

Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab (Humira) plus MTX in MTX inadequate responders using ACR50 at Month 6 as the primary endpoint. There were three comparisons,which found:

more...
2/9/17 8:30am EST
Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases

Logan Levkoff, Ph.D., addresses tough topics for those living with rheumatoid arthritis on Arthritis.com

Nationally-recognized relationship expert and author, Logan Levkoff, Ph.D., has partnered with Pfizer Inc. (NYSE:PFE) to fill a void in information available to people living with chronic diseases: relationship advice. Levkoff will address the topics of relationships and intimacy for those living with a chronic condition, like rheumatoid arthritis (RA), on the newly re-launched Arthritis.com site. The website is a place where people living with a chronic illness can find inspiration, lifestyle advice, tools, and disease information.

more...
1/31/17 6:45am EST
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2016 RESULTS

PROVIDES 2017 FINANCIAL GUIDANCE

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink: http://www.pfizer.com/system/files/presentation/Q4_2016_PFE_Earnings_Pre...

more...

Pages